How Freshdesk and Freshservice Work Together to Improve Support and IT Services 
ER2 Improves Ecommerce Fulfillment Nationwide with Descartes Solution Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical,…
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical,…
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409…
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409…
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour…
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour…
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD…
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD…
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience…
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience…
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via…
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via…
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano,…
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano,…
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical…
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical…
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including…
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including…